Tony Butler : I appreciate that. I think there are some clinical models which suggest that there are differences, RCC being one and clearly one being another, but it’s irrelevant maybe as it applies to where these are at least being tested. So I’m grateful for that, Bob. Thank you.
Operator: Our next question is from the line of Kumar Raja with Roth Capital Partners. Please go ahead.
Kumar Raja : Thanks for taking my questions. Again, with regard to the MANTRA-2, part B, where you are thinking about one or two histologies, how do we get there given that we are seeing such a diverse histology in the interim data?
Avanish Vellanki : Sure. Hi Kumar. Yes, so the question was with respect to path B of the scenarios we’re considering from MANTRA-2, how do we get there? Because we’ve already seen — we’ve already seen activity across multiple tumor types. Is that did I restate that correctly?
Kumar Raja : Yes. I’m also trying to get a sense like whether you think that there will be it’ll be engaging for some populations there or just trying to get a sense how we get from like seven or eight to like one or two?
Avanish Vellanki : Yes. So just as a reminder, I’ll take this one. As a reminder, we showed two early unconfirmed PRs. One of those patients with the PR was going to remain unconfirmed because of a death due to COVID, and we had two near PRs. So as of the cutoff back in October, so four different tumor types with encouraging activity, now since that moment in time, we’re not revealing any additional patient data, but we’d want to make sure that we see meaningful confirmed responses, again, preferably across a range of tumor types. Now, I think scenario B, path B as we highlighted suggested that if we start seeing confirmed responses with a meaningful durability in a couple of tumor types, maybe a few tumor types, that would be the scenario.
Where we also do not see confirmed responses in a range of other tumor types. So from the point of interim data release, again, we’re not providing you any additional color on this call, but I think we would want to see confirmed responses with meaningful durability of response. And if we see that only in a few tumor types, that would be the path B that we highlighted. Did that answer your question?
Kumar Raja: Yes. And also in terms of the patient population size, right, like looks like breast and lung cancer as well as bladder, those are the predominant ones with greater than eight copy number. So how should we think about it?
Avanish Vellanki: It’s still too early to tell, but I’ll ask Bob to review for the MDM2 amp patient frequencies, what the top tumor types are just in terms of absolute patient numbers, but we are too early to make a call on where it’s going to go.
Robert Doebele: Yes. You’ll recall that the top three tumor types are breast, lung, and bladder. So those three tumor types comprise about 75% of all the MDM2 amplified patients. Obviously, they have a very large incidence in their own right. And so the majority of MDM2 amplified patients fall into one of those three tumor histologies. The remaining 25% are obviously are made up of multiple different tumor types.
Kumar Raja: Okay, great. Thanks.
Operator: As there are no further questions at this time, I would like to turn the floor back over to Avanish Vellanki for closing comments.
